Forbes

Is There A Smart Way To Use The New Oncotype Prostate Cancer Test?

Forbes contributors publish independent expert analyses and insights. I am a physician and behavioral scientist at Duke University. This article is more than 10 years old. On May 8 th, the makers of ...
Nature

Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions

In this study, we reviewed the clinical, morphologic, and immunophenotypic data of DCIS cases sent for Oncotype DCIS at our institution, and analyzed whether any features were predictive of the ...
Psychology Today

Psychology Today

On May 8th, the makers of the oncotype DX Prostate Cancer Test presented results of a large study demonstrating that their test can help men decide whether their prostate cancer carries a low enough ...
Nasdaq

New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage ...

REDWOOD CITY, Calif., Aug. 21, 2019 /PRNewswire/ -- Genomic Health today announced that, based on results from the prospective TAILORx1 and PlanB2 studies, the 16th St. Gallen International Breast ...
Forbes

Oncotype Test Could Reduce Overtreatment Of Early Stage Breast Cancer

Forbes contributors publish independent expert analyses and insights. I cover cancer science, treatments and attitudes. A key finding is that a low Oncotype DX DCIS Score™ conferred a low chance of ...
Business Insider

New NCCN Breast Cancer Guidelines Elevate Oncotype DX Breast Recurrence Score® as the Only Preferred Multi-gene Test to Predict Chemotherapy Treatment

REDWOOD CITY, Calif., Oct. 9, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that its Oncotype DX Breast Recurrence Score ® test has been categorized as the only "preferred" ...
Seeking Alpha

JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups

Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...
ascopubs.org

Is Oncotype DX test necessary for T1b grade 1, hormone receptor positive HER-2 negative breast cancer? A single institution retrospective analysis.

Changes in bone mineral density with adjuvant aromatase inhibitor treatment and breast cancer recurrence. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract does not ...
Nasdaq

Exact Sciences Introduces the Oncotype MAP™ Pan-Cancer Tissue Test to Help Guide Treatment for Patients with Advanced Cancer

MADISON, Wis., Oct. 12, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced the introduction of the Oncotype MAP™ Pan-Cancer Tissue test for patients with advanced, metastatic, ...
ascopubs.org

Budget Impact of the Oncotype DX Test in Early-Stage Breast Cancer for the Brazilian Private Health Care System

Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...
Time

Genetic Test Impacts Chemo Choices In Surprising Ways

In the new era of personalized medicine, having more information on hand is considered the ideal situation for making more customized, and ideally, effective decisions about medical care. And in a new ...